Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 279

1.

Fra-1/AP-1 induces EMT in mammary epithelial cells by modulating Zeb1/2 and TGFβ expression.

Bakiri L, Macho-Maschler S, Custic I, Niemiec J, Guío-Carrión A, Hasenfuss SC, Eger A, Müller M, Beug H, Wagner EF.

Cell Death Differ. 2015 Feb;22(2):336-50. doi: 10.1038/cdd.2014.157. Epub 2014 Oct 10.

2.

Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression.

Csiszar A, Kutay B, Wirth S, Schmidt U, Macho-Maschler S, Schreiber M, Alacakaptan M, Vogel GF, Aumayr K, Huber LA, Beug H.

Breast Cancer Res. 2014 Sep 9;16(5):433. doi: 10.1186/s13058-014-0433-7.

3.

Semaphorin-7a reverses the ERF-induced inhibition of EMT in Ras-dependent mouse mammary epithelial cells.

Allegra M, Zaragkoulias A, Vorgia E, Ioannou M, Litos G, Beug H, Mavrothalassitis G.

Mol Biol Cell. 2012 Oct;23(19):3873-81. doi: 10.1091/mbc.E12-04-0276. Epub 2012 Aug 8.

4.

Diverging fates of cells of origin in acute and chronic leukaemia.

Kovacic B, Hoelbl A, Litos G, Alacakaptan M, Schuster C, Fischhuber KM, Kerenyi MA, Stengl G, Moriggl R, Sexl V, Beug H.

EMBO Mol Med. 2012 Apr;4(4):283-97. doi: 10.1002/emmm.201100208. Epub 2012 Feb 9.

5.

Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.

Grebien F, Hantschel O, Wojcik J, Kaupe I, Kovacic B, Wyrzucki AM, Gish GD, Cerny-Reiterer S, Koide A, Beug H, Pawson T, Valent P, Koide S, Superti-Furga G.

Cell. 2011 Oct 14;147(2):306-19. doi: 10.1016/j.cell.2011.08.046.

6.

p38α controls erythroblast enucleation and Rb signaling in stress erythropoiesis.

Schultze SM, Mairhofer A, Li D, Cen J, Beug H, Wagner EF, Hui L.

Cell Res. 2012 Mar;22(3):539-50. doi: 10.1038/cr.2011.159. Epub 2011 Sep 27.

7.

La enhances IRES-mediated translation of laminin B1 during malignant epithelial to mesenchymal transition.

Petz M, Them N, Huber H, Beug H, Mikulits W.

Nucleic Acids Res. 2012 Jan;40(1):290-302. doi: 10.1093/nar/gkr717. Epub 2011 Sep 6.

8.

Membrane lipidome of an epithelial cell line.

Sampaio JL, Gerl MJ, Klose C, Ejsing CS, Beug H, Simons K, Shevchenko A.

Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):1903-7. doi: 10.1073/pnas.1019267108. Epub 2011 Jan 18.

9.

Annexin A1 attenuates EMT and metastatic potential in breast cancer.

Maschler S, Gebeshuber CA, Wiedemann EM, Alacakaptan M, Schreiber M, Custic I, Beug H.

EMBO Mol Med. 2010 Oct;2(10):401-14. doi: 10.1002/emmm.201000095.

10.

Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation.

Friedbichler K, Kerenyi MA, Kovacic B, Li G, Hoelbl A, Yahiaoui S, Sexl V, Müllner EW, Fajmann S, Cerny-Reiterer S, Valent P, Beug H, Gouilleux F, Bunting KD, Moriggl R.

Blood. 2010 Sep 2;116(9):1548-58. doi: 10.1182/blood-2009-12-258913. Epub 2010 May 27.

11.

NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells.

Maier HJ, Schmidt-Strassburger U, Huber MA, Wiedemann EM, Beug H, Wirth T.

Cancer Lett. 2010 Sep 28;295(2):214-28. doi: 10.1016/j.canlet.2010.03.003. Epub 2010 Mar 29.

PMID:
20350779
12.

Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia.

Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G, Hennighausen L, Poli V, Beug H, Moriggl R, Sexl V.

EMBO Mol Med. 2010 Mar;2(3):98-110. doi: 10.1002/emmm.201000062.

13.

A novel conserved phosphotyrosine motif in the Drosophila fibroblast growth factor signaling adaptor Dof with a redundant role in signal transmission.

Csiszar A, Vogelsang E, Beug H, Leptin M.

Mol Cell Biol. 2010 Apr;30(8):2017-27. doi: 10.1128/MCB.01436-09. Epub 2010 Feb 12.

14.

BI 5700, a Selective Chemical Inhibitor of IκB Kinase 2, Specifically Suppresses Epithelial-Mesenchymal Transition and Metastasis in Mouse Models of Tumor Progression.

Huber MA, Maier HJ, Alacakaptan M, Wiedemann E, Braunger J, Boehmelt G, Madwed JB, Young ER, Marshall DR, Pehamberger H, Wirth T, Kraut N, Beug H.

Genes Cancer. 2010 Feb;1(2):101-14. doi: 10.1177/1947601910361749.

15.

Epithelial-mesenchymal transition in pancreatic carcinoma.

Maier HJ, Wirth T, Beug H.

Cancers (Basel). 2010 Dec 9;2(4):2058-83. doi: 10.3390/cancers2042058.

16.

Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence.

Zulehner G, Mikula M, Schneller D, van Zijl F, Huber H, Sieghart W, Grasl-Kraupp B, Waldhör T, Peck-Radosavljevic M, Beug H, Mikulits W.

Am J Pathol. 2010 Jan;176(1):472-81. doi: 10.2353/ajpath.2010.090300. Epub 2009 Dec 11.

17.

Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge.

van Zijl F, Mair M, Csiszar A, Schneller D, Zulehner G, Huber H, Eferl R, Beug H, Dolznig H, Mikulits W.

Oncogene. 2009 Nov 12;28(45):4022-33. doi: 10.1038/onc.2009.253. Epub 2009 Aug 31.

18.

Breast cancer stem cells: eradication by differentiation therapy?

Beug H.

Cell. 2009 Aug 21;138(4):623-5. doi: 10.1016/j.cell.2009.08.007.

19.

The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor.

Ecker A, Simma O, Hoelbl A, Kenner L, Beug H, Moriggl R, Sexl V.

Front Biosci (Landmark Ed). 2009 Jan 1;14:2944-58.

PMID:
19273247
20.

ILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progression.

Lahsnig C, Mikula M, Petz M, Zulehner G, Schneller D, van Zijl F, Huber H, Csiszar A, Beug H, Mikulits W.

Oncogene. 2009 Feb 5;28(5):638-50. doi: 10.1038/onc.2008.418. Epub 2008 Nov 17.

21.

Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1.

Kerenyi MA, Grebien F, Gehart H, Schifrer M, Artaker M, Kovacic B, Beug H, Moriggl R, Müllner EW.

Blood. 2008 Nov 1;112(9):3878-88. doi: 10.1182/blood-2008-02-138339. Epub 2008 Aug 11.

22.

Igbp1 is part of a positive feedback loop in stem cell factor-dependent, selective mRNA translation initiation inhibiting erythroid differentiation.

Grech G, Blázquez-Domingo M, Kolbus A, Bakker WJ, Müllner EW, Beug H, von Lindern M.

Blood. 2008 Oct 1;112(7):2750-60. doi: 10.1182/blood-2008-01-133140. Epub 2008 Jul 14.

23.

Cellular repressor of E1A-stimulated genes is a bona fide lysosomal protein which undergoes proteolytic maturation during its biosynthesis.

Schähs P, Weidinger P, Probst OC, Svoboda B, Stadlmann J, Beug H, Waerner T, Mach L.

Exp Cell Res. 2008 Oct 1;314(16):3036-47. doi: 10.1016/j.yexcr.2008.06.015. Epub 2008 Jun 28.

PMID:
18621046
24.

The different functions of Stat5 and chromatin alteration through Stat5 proteins.

Kornfeld JW, Grebien F, Kerenyi MA, Friedbichler K, Kovacic B, Zankl B, Hoelbl A, Nivarti H, Beug H, Sexl V, Muller M, Kenner L, Mullner EW, Gouilleux F, Moriggl R.

Front Biosci. 2008 May 1;13:6237-54. Review.

25.

Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2.

Grebien F, Kerenyi MA, Kovacic B, Kolbe T, Becker V, Dolznig H, Pfeffer K, Klingmüller U, Müller M, Beug H, Müllner EW, Moriggl R.

Blood. 2008 May 1;111(9):4511-22. doi: 10.1182/blood-2007-07-102848. Epub 2008 Jan 31.

26.

Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis.

Gal A, Sjöblom T, Fedorova L, Imreh S, Beug H, Moustakas A.

Oncogene. 2008 Feb 21;27(9):1218-30. Epub 2007 Aug 27.

PMID:
17724470
27.

Direct glucocorticoid receptor-Stat5 interaction in hepatocytes controls body size and maturation-related gene expression.

Engblom D, Kornfeld JW, Schwake L, Tronche F, Reimann A, Beug H, Hennighausen L, Moriggl R, Schütz G.

Genes Dev. 2007 May 15;21(10):1157-62.

28.

c-Myc is required for transformation of FDC-P1 cells by EGFRvIII.

Rath O, Himmler A, Baum A, Sommergruber W, Beug H, Metz T.

FEBS Lett. 2007 May 29;581(13):2549-56. Epub 2007 May 8.

29.

The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity.

Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, Mikulits W, Brabletz T, Strand D, Obrist P, Sommergruber W, Schweifer N, Wernitznig A, Beug H, Foisner R, Eger A.

Oncogene. 2007 Oct 25;26(49):6979-88. Epub 2007 May 7.

30.

p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway.

Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, Komnenovic V, Scheuch H, Beug H, Wagner EF.

Nat Genet. 2007 Jun;39(6):741-9. Epub 2007 Apr 29.

PMID:
17468757
31.

The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression.

Aigner K, Descovich L, Mikula M, Sultan A, Dampier B, Bonné S, van Roy F, Mikulits W, Schreiber M, Brabletz T, Sommergruber W, Schweifer N, Wernitznig A, Beug H, Foisner R, Eger A.

FEBS Lett. 2007 Apr 17;581(8):1617-24. Epub 2007 Mar 21.

32.

Differential regulation of Foxo3a target genes in erythropoiesis.

Bakker WJ, van Dijk TB, Parren-van Amelsvoort M, Kolbus A, Yamamoto K, Steinlein P, Verhaak RG, Mak TW, Beug H, Löwenberg B, von Lindern M.

Mol Cell Biol. 2007 May;27(10):3839-3854.

33.

LAP2alpha-binding protein LINT-25 is a novel chromatin-associated protein involved in cell cycle exit.

Naetar N, Hutter S, Dorner D, Dechat T, Korbei B, Gotzmann J, Beug H, Foisner R.

J Cell Sci. 2007 Mar 1;120(Pt 5):737-47. Epub 2007 Feb 6.

34.

PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression.

Fischer AN, Fuchs E, Mikula M, Huber H, Beug H, Mikulits W.

Oncogene. 2007 May 17;26(23):3395-405. Epub 2006 Nov 20.

PMID:
17130832
35.

Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias.

Harir N, Pecquet C, Kerenyi M, Sonneck K, Kovacic B, Nyga R, Brevet M, Dhennin I, Gouilleux-Gruart V, Beug H, Valent P, Lassoued K, Moriggl R, Gouilleux F.

Blood. 2007 Feb 15;109(4):1678-86. Epub 2006 Oct 12.

36.

ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells.

Waerner T, Alacakaptan M, Tamir I, Oberauer R, Gal A, Brabletz T, Schreiber M, Jechlinger M, Beug H.

Cancer Cell. 2006 Sep;10(3):227-39.

37.

Acetylation and MAPK phosphorylation cooperate to regulate the degradation of active GATA-1.

Hernandez-Hernandez A, Ray P, Litos G, Ciro M, Ottolenghi S, Beug H, Boyes J.

EMBO J. 2006 Jul 26;25(14):3264-74. Epub 2006 Jul 6.

38.

STAT1 acts as a tumor promoter for leukemia development.

Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, Levy DE, Beug H, Freissmuth M, Sexl V.

Cancer Cell. 2006 Jul;10(1):77-87.

39.

Raf plus TGFbeta-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin.

Janda E, Nevolo M, Lehmann K, Downward J, Beug H, Grieco M.

Oncogene. 2006 Nov 16;25(54):7117-30. Epub 2006 Jun 5.

PMID:
16751808
40.

Autocrine PDGFR signaling promotes mammary cancer metastasis.

Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, Donovan M, Cordon-Cardo C, Beug H, Grünert S.

J Clin Invest. 2006 Jun;116(6):1561-70.

41.

A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes.

Gotzmann J, Fischer AN, Zojer M, Mikula M, Proell V, Huber H, Jechlinger M, Waerner T, Weith A, Beug H, Mikulits W.

Oncogene. 2006 May 25;25(22):3170-85.

PMID:
16607286
42.

A balance between Raf-1 and Fas expression sets the pace of erythroid differentiation.

Rubiolo C, Piazzolla D, Meissl K, Beug H, Huber JC, Kolbus A, Baccarini M.

Blood. 2006 Jul 1;108(1):152-9. Epub 2006 Mar 9.

43.

Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation.

Hoelbl A, Kovacic B, Kerenyi MA, Simma O, Warsch W, Cui Y, Beug H, Hennighausen L, Moriggl R, Sexl V.

Blood. 2006 Jun 15;107(12):4898-906. Epub 2006 Feb 21.

44.

Remodeling the regulation of iron metabolism during erythroid differentiation to ensure efficient heme biosynthesis.

Schranzhofer M, Schifrer M, Cabrera JA, Kopp S, Chiba P, Beug H, Müllner EW.

Blood. 2006 May 15;107(10):4159-67. Epub 2006 Jan 19.

45.

Erythroid progenitor renewal versus differentiation: genetic evidence for cell autonomous, essential functions of EpoR, Stat5 and the GR.

Dolznig H, Grebien F, Deiner EM, Stangl K, Kolbus A, Habermann B, Kerenyi MA, Kieslinger M, Moriggl R, Beug H, Müllner EW.

Oncogene. 2006 May 11;25(20):2890-900.

46.

Molecular requirements for epithelial-mesenchymal transition during tumor progression.

Huber MA, Kraut N, Beug H.

Curr Opin Cell Biol. 2005 Oct;17(5):548-58. Review.

PMID:
16098727
47.

HOXB4 enforces equivalent fates of ES-cell-derived and adult hematopoietic cells.

Pilat S, Carotta S, Schiedlmeier B, Kamino K, Mairhofer A, Will E, Modlich U, Steinlein P, Ostertag W, Baum C, Beug H, Klump H.

Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12101-6. Epub 2005 Aug 10.

48.

Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth.

Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal K, Beug H, Ohlschläger P, Schütz A, Halbhuber KJ, Friedrich K.

Neoplasia. 2005 Jun;7(6):545-55.

49.

The erythroid phenotype of EKLF-null mice: defects in hemoglobin metabolism and membrane stability.

Drissen R, von Lindern M, Kolbus A, Driegen S, Steinlein P, Beug H, Grosveld F, Philipsen S.

Mol Cell Biol. 2005 Jun;25(12):5205-14.

50.

Integration of Ras subeffector signaling in TGF-beta mediated late stage hepatocarcinogenesis.

Fischer AN, Herrera B, Mikula M, Proell V, Fuchs E, Gotzmann J, Schulte-Hermann R, Beug H, Mikulits W.

Carcinogenesis. 2005 May;26(5):931-42. Epub 2005 Feb 10.

PMID:
15705598

Supplemental Content

Support Center